Overview

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

Status:
Completed
Trial end date:
2017-06-29
Target enrollment:
Participant gender:
Summary
This is an open-label, phase II study of BI 695501 to assess handling experience of patients with Rheumatoid Arthritis using an autoinjector. The extension phase is to provide patients with additional exposure to BI 695501 and to enhance the safety database for this compound.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim